None listed
Conditions
Brief summary
During the COVID-19 Pandemic a number of medical and allied health consultations has been changed from face-to-face to telehealth, using either telephone or video. This study would like to understand the level of satisfaction melanoma patients and their clinicians had with telehealth. Learning about the satisfaction may lead to improvement of this service in the future, as telehealth may be able to bridge geographical gaps many patients experience who do not live in large urban areas. Who is this study for? Patients: This study may be suitable for you if you are: at least 18 years of age, able to read and understand English and respond to survey questions, are able to provide informed consent, you have been diagnosed with melanoma, you have had at least one consultation via telehealth since March 2020, you are receiving services from healthcare professionals at Melanoma Institute Australia, or Melanoma and Surgical Oncology at Royal Prince Alfred Hospital Clinicians: This study may be suitable for you if you are: a healthcare professional (e.g. doctor, nurse, allied health) involved in providing care, support, and management of patients with melanoma, providing services at Melanoma Institute Australia and Royal Prince Alfred Hospital, you have provided at least one telehealth consultation in relation to melanoma management since March 2020. Study details: Participants enrolled in this study will be asked to complete ONE survey. Melanoma patients will be able to complete this survey online or in paper form. This survey will take about 20 minutes to complete and will contain questions about general demographic and melanoma information, satisfaction with telehealth, emotional and physical functioning, Clinicians will, be asked to complete a 10 minute survey containing questions about their general demographic information, their career stage, opinion about adequacy of Medicare items for telehealth as well as their own perception of telehealth they provided. Clinician survey will be available online. It is hoped that this study will highlight the benefits of telehealth, as well as some areas where improvements may be needed. This may lead to implementation of the strategies to address areas of low satisfaction in both clinical practice as well as research.
Interventions
This study is interested in exploring melanoma patients' and clinicians' satisfaction with telehealth that they received during COVID-19 pandemic as well as factors that may be associated with this satisfaction.
Patients will be required to complete one 20-minute survey. Patients will self-select to participate in the study and can choose whether this survey is completed in the paper form, or online (via REDCap). For online completion, the patients will be required to complete the survey in
This study is interested in exploring melanoma patients' and clinicians' satisfaction with telehealth that they received during COVID-19 pandemic as well as factors that may be associated with this satisfaction. Patients will be required to complete one 20-minute survey. Patients will self-select to participate in the study and can choose whether this survey is completed in the paper form, or online (via REDCap). For online completion, the patients will be required to complete the survey in one sitting. Patient survey will contain demographic (birth year, gender, living arrangements, language spoken at home, health insurance status, employment status, highest educational attainment, postcode of primary residence, annual income) and clinical (time since diagnosis, melanoma stage, past and current treatments for melanoma, current melanoma status) questions, information about telehealth received (when was the most recent telehealth consultation, type of telehealth, whether it was a part of clinical trial), the measure of their satisfaction with telehealth they received during COVID-19 (Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ), additional Likert and qualitative questions), trust in oncologist (Trust in Oncologist Scale (TiOS-SF)), quality of life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Melanoma Concerns Questionnaire (MCQ-28)), Fear of Cancer Recurrence (Fear of Cancer Recurrence Short Form Inventory (FCRI-SF)). Clinicians will also self-select to participate in this study. They will be required to answer one 10 minute survey containing demographic (birth year, gender) and professional (profession/specialisation, career stage, years working in melanoma), information about most recent telehealth consultation provided (month of this consultation, mode of delivery, whether it was a part of a clinical trial), information about the adequacy of MBS item numbers for telehealth, measurement of satisfaction with telehealth (Health Optimum Telemedicine Acceptance Questionnaire, additional Likert and qualitative questions)
Sponsors
Melanoma Institute Australia
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients: - 18 years of age. - Able to read and understand English and respond to study questions - Cognitive capacity to provide informed consent. - Diagnosis of melanoma (any stage). - Participation in at least on telehealth consultation in relation to their melanoma since March 2020. - Receiving services from healthcare professionals at one of the study sites. Clinicians - Healthcare professional (e.g. doctor, nurse, allied health) involved in providing care, support, and management of patients with melanoma. - Providing services within the study sites that are approved for this study. - Provision of at least one telehealth consultation in relation to melanoma management since March 2020.
Exclusion criteria
Patients: - Younger than 18 years of age. - Insufficient English and/or cognitive ability to understand and respond to study materials. - Diagnosis of any other skin condition, including non-melanoma skin cancer - Participation in telehealth. consultations that are not related to melanoma management. Clinicians - Practicing outside the approved study sites. - Providing only face to face consultations during COVID-19 (since March 2020) - Not involved in care of melanoma patients. - Participation in an interview as a part of ‘The Management of Primary Melanoma in the Time of COVID-19; Lessons and Future Directions’
Outcome results
None listed